Anavex Life Sciences
AVXL
153 hedge funds and large institutions have $245M invested in Anavex Life Sciences in 2023 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 56 increasing their positions, 36 reducing their positions, and 17 closing their positions.
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
56% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 36
49% more capital invested
Capital invested by funds: $164M → $245M (+$80.9M)
7% more funds holding
Funds holding: 143 → 153 (+10)
1.49% more ownership
Funds ownership: 30.58% → 32.07% (+1.5%)
47% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $21.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.35M |
| 2 |
BlackRock
New York
|
+$4.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$794K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$715K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.08M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.02M |
| 4 |
Two Sigma Investments
New York
|
-$568K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$395K |
AVXL Hedge Fund Activity: Q4 2023 in Review
153 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q4 2023, worth a combined $245M — up 49% from $164M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new AVXL positions and 17 closed out — a net gain of 10 holders — while 56 added to existing stakes and 36 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.35M. The largest seller was Millennium Management, cutting an estimated $4.8M.
- 153 institutional investors held Anavex Life Sciences (AVXL) as of Q4 2023, up from 143 in Q3 2023.
- Funds reported $245M of Anavex Life Sciences stock for Q4 2023, up 49% quarter-over-quarter.
- 27 funds opened new Anavex Life Sciences positions in Q4 2023 and 17 closed out, a net change of +10 holders.
- The largest Anavex Life Sciences buyer in Q4 2023 was Morgan Stanley, an estimated $4.35M added.
- The largest Anavex Life Sciences seller in Q4 2023 was Millennium Management, an estimated $4.8M sold.
Based on aggregated 13F filings for Q4 2023.